Ipamorelin Dosage in the Research: Doses, Routes & Half-Life
The gist
This page is about Ipamorelin dosage as it appears in studies — not a how-to. It reports what researchers gave, to which animals or volunteers, by which route, and how fast it cleared. It is not a recommendation, and there is no proven human dose for any everyday use. The numbers worth holding onto: the only human data used intravenous infusions, the half-life is about two hours, and the GH pulse peaks around 40 minutes after dosing. Animal studies used a wide range of doses and routes — under the skin, into the vein, into the abdomen — depending on what they were measuring. The popular CJC-1295 pairing has no controlled human dosing basis at all. Everything below is third person and study-attributed; none of it tells you what to take.
Doses and routes that appear in the literature
The studied range is wide because the questions differed. In the human PK/PD study, healthy male volunteers received 4.21-140.45 nmol/kg IV over 15 minutes as single doses [2]. The human Phase 2 ileus trial used 0.03 mg/kg IV twice daily for up to 7 days [3]. A rat bone-growth study used 18, 90, and 450 μg/day subcutaneously, divided three times daily over 15 days [4]. Rat postoperative-ileus work used 0.1-1 mg/kg IV repeated four times daily [7], and a gastric-emptying study used 0.014 and 0.14 μmol/kg IV [8]. The 2024 ferret cachexia study used 1-3 mg/kg intraperitoneally [5]. Routes studied across the record include intravenous (human and rodent), subcutaneous (rodent body-composition work and the dominant route in community use), intranasal (rodent, ~20% bioavailability), and intraperitoneal (rodent/ferret). Ipamorelin itself is not orally bioavailable; only engineered analogs show oral activity.
Half-life and timing
The terminal half-life is approximately 2 hours in healthy human volunteers given IV ipamorelin, with clearance 0.078 L/h/kg and steady-state volume of distribution 0.22 L/kg [2]. The GH response is not sustained — it is a single discrete pulse peaking at roughly 40 minutes (0.67 h) after dosing [2]. In rats, plasma clearance is roughly 5-fold lower than GHRP-6. This short, pulsatile profile is why the compound is studied as a pulse-generator rather than a steady-state hormone, and it is the single most useful timing fact in the human record.
How much cjc-1295 ipamorelin should i take
There is no established or evidence-based human dose for the CJC-1295 + ipamorelin combination, and this site does not provide one. The popular subcutaneous "stack" protocols circulating in peptide communities pair the two compounds, but those regimens have no peer-reviewed human dosing basis — they are anecdotal, not recommended [3]. What the literature contains is single-agent research dosing: ipamorelin's human exposures were intravenous infusions in tightly controlled settings [2], not the self-administered subcutaneous routines described online. The combination has never been tested for any outcome in a controlled human trial, so any specific microgram figure repeated in forums is community lore, not science.
How to reconstitute cjc-1295 ipamorelin 5mg
Reconstitution is a research-handling topic, not a clinical-preparation instruction, and nothing here is a directive to prepare an injection. As a general note from the research-supply literature: ipamorelin is supplied as a lyophilized (freeze-dried) powder, as free base or acetate salt, and is dissolved with bacteriostatic water for laboratory handling. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated [2]. Exact volumes depend on the powder mass and the concentration a protocol calls for — a 5 mg vial dissolved in a larger volume yields a more dilute solution than the same mass in a smaller volume. These are handling observations only; this site gives no human preparation or injection guidance.